LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory

Stock News

2025/12/07

LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the "National Reimbursement Drug List (2025)" or the "Commercial Health Insurance Innovative Drug Directory (2025)" issued by the National Healthcare Security Administration.

The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1151283630"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151283630\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151283630?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151283630","market":"nz","top_or_hot":-1,"title":"LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory","media":"Stock News","content":"<p>LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.</p>\n<p>The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.</p>\n<p>The five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1151283630","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151283630","pubTimestamp":1765104372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1191":"制药","06978":"永泰生物-B","BK1606":"中医药概念","BK1161":"生物科技","BK1574":"生物医药B类股","02186":"绿叶制药","BK1583":"高瓴概念"},"translate_title":"绿叶制药(02186)五款新品成功纳入2025年国家报销药品目录或商保创新药目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"02186":1,"06978":1},"content_text":"LUYE PHARMA (02186) announced that five of its new products have been successfully included in either the \"National Reimbursement Drug List (2025)\" or the \"Commercial Health Insurance Innovative Drug Directory (2025)\" issued by the National Healthcare Security Administration.\nThe five newly included products are: Mephiboxin® (Oxycodone Naloxone Extended-Release Tablets) and Rebalax® (Paliperidone Palmitate Injection (II)), which were newly added to the National Reimbursement Drug List; Zanbika® (Lurbinectedin for Injection) was selected for the Commercial Insurance Innovative Drug Directory; while Betovel® (Goserelin Acetate Microspheres for Injection) and Rekotuo® (Risperidone Microspheres for Injection (II)) were successfully renewed and remain on the National Reimbursement Drug List.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}